Who We Are
At Simurx, we are driven by a deep commitment to scientific excellence and an unwavering determination to enhance outcomes for cancer patients. Our team of scientists has pioneered the CTSR platform, a groundbreaking technology that harnesses the immunosuppressive properties of the tumor microenvironment to significantly improve the efficacy of cell therapies. This innovation is protected by a comprehensive patent portfolio.
Our multidisciplinary and integrative approach to product development ensures that we remain at the forefront of cancer therapy innovation. With our cutting-edge technology, Simurx is uniquely positioned to deliver a wide range of multifunctional CAR T-cell therapies, offering new hope to cancer patients around the world.
Our Platform
Our patented chimeric TGFβ-signaling receptor (CTSR) platform promotes survival in a hostile tumor environment and can be modularly combined with other engineered cell therapies
The Science
The CTSR platform soaks up immunosuppressive molecules from the tumor microenvironment while promoting CAR-T proliferation and immune activation.
Our Pipeline
The modular design and inherent flexibility of the CTSR platform allow its incorporation into a multitude cellular therapies
Latest News
Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children
Regenerative medicine promises novel CAR T-cell therapies for metastatic solid tumors. LOS ANGELES (February 29, 2024)—Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors. The Cancer […]
Eurekalert: Children’s Hospital Los Angeles awarded $6 million from CIRM to advance CAR T-cell therapies
Regenerative medicine promises novel CAR T-cell therapies for metastatic solid tumors. Grant and Award Announcement CHILDREN’S HOSPITAL LOS ANGELES CREDIT: CHLA LOS ANGELES (February 29, 2024)—Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches […]
Business Wire: Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies
Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children Business Wire Fri, Mar 1, 2024 Shahab Asgharzadeh, MD, Director, Neuroblastoma Basic and Translational Program, Division of Hematology-Oncology at The Saban Research Institute of Children’s Hospital Los Angeles and lead […]